Prostaglandins and chemokines are powerful signaling molecules that influence inflammation, immune responses, and tissue function. Among these, Prostaglandin D₂ (PGD₂), Prostaglandin F₂α (PGF₂α), Prostaglandin E₂ (PGE₂), and Eotaxin‑1 (CCL11) are gaining clinical interest for their roles in a variety of chronic inflammatory conditions, including neurodegenerative disease, allergic responses, and mast cell activation syndrome (MCAS).
PGD₂, primarily released by mast cells, plays a role in allergic inflammation and neuroimmune processes. In animal models of Alzheimer’s disease, elevated PGD₂ has been linked to cognitive decline and increased expression of pro-inflammatory receptors. This same mediator is often elevated in MCAS, contributing to common symptoms like brain fog, fatigue, and flushing. New research into DP₂ receptor antagonists offers potential therapeutic targets for PGD₂-related inflammation.
PGE₂ is a critical regulator in respiratory and renal systems. In cystic fibrosis, high levels of PGE₂ have been associated with more severe disease presentations. It also plays a role in bladder function and is suspected to contribute to urinary urgency and pelvic discomfort, symptoms frequently reported by patients with MCAS or interstitial cystitis. PGF₂α, more commonly recognized in reproductive health, also influences smooth muscle function and may play a role in MCAS-related menstrual irregularities or gastrointestinal symptoms.
Eotaxin‑1 (CCL11), a chemokine involved in eosinophil recruitment, is elevated in asthma, inflammatory bowel disease, and even osteoarthritis. It’s also been linked to neuroinflammation and cognitive decline, making it relevant to both MCAS and long COVID symptom profiles.
Together, these mediators form a critical inflammatory fingerprint. Measuring them may provide deeper insight into complex syndromes like MCAS and help guide targeted interventions in patients with chronic, multisystem inflammatory symptoms.
References
Gärtner et al. (2024). Journal of Clinical Medicine, 13(7), 2050. https://doi.org/10.3390/jcm13072050
Andersson & Fu (2020). Frontiers in Physiology. https://doi.org/10.3389/fphys.2020.00705
Teixeira et al. (2018). Frontiers in Psychiatry, 9, 241. https://doi.org/10.3389/fpsyt.2018.00241